Ricerc@Sapienza

BACKGROUND Long-term real-world data are relatively sparse regarding recurrence of chronic hepatitis B virus (HBV) infection after liver transplantation using hepatitis B immunoglobulin (HBIg) and nucleos(t)ide analogue (NUC) prophylaxis. MATERIAL AND METHODS Data from 371 adults transplanted for HBV-related disease at 20 European centers and given HBIg for ³12 months ± NUC therapy were analyzed retrospectively. RESULTS HBIg comprised Hepatect® (iv HBIgB; n=299), subcutaneous Zutectra® (sc HBIg, n=236), and other HBIg preparations (n=130); 93.5% received NUC therapy.

Hepatocellular carcinoma (HCC), is one of the most frequent human cancer and is characterized
by a high mortality rate. The aggressiveness appears strictly related to the liver pathological background on
which cancer develops. Inflammation and the consequent fibro/cirrhosis, derived from chronic injuries of
several origins (viral, toxic and metabolic) and observable in almost all oncological patients, represents the
most powerful risk factor for HCC and, at the same time, an important obstacle to the efficacy of systemic